EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Oncogenic EGFR Signaling as a Central Regulator of Chemoresistance in Ovarian Cancer: A Mechanistic Review

Arulkumar Nagappan iD, Veeran Sethuraman iD, Parthiban Pandian iD, Jothi Nedunchezhian, Arvind Kumar Shukla iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27135937 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Arulkumar Nagappan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, T…. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Ovarian Neoplasms, Signal Transduction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer (OVC) is a leading cause of gynecological cancer mortality due to late-stage diagnosis and chemoresistance. Among the multiple molecular mediators, oncogenic epidermal growth factor receptor (EGFR) signaling has emerged as a key regulator of tumor progression and drug resistance, ultimately governing cancer survival. Therefore, this review focused on the molecular mechanisms of aberrant EGFR signaling to promote chemoresistance in ovarian cancer through multiple interlinking pathways, including the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of the rapamycin (mTOR), mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), and Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling cascades. These pathways act in concert to confer resistance, including proliferation, antiapoptotic effects, cancer stem cell maintenance, and facilitating epithelial-mesenchymal transition (EMT), which function together to decrease sensitivity towards platinum-based and taxane chemotherapies. Furthermore, we incorporate novel evidence regarding EGFR cross-talk with extracellular matrix (ECM) and metabolic reprogramming, especially their relevance to immune evasion mechanisms, hypoxia, and extracellular vesicles (EVs)-mediated signaling. In addition, we elaborated on the limitation of the current EGFR targeting therapy, which will be beneficial for further designing new combinatorial treatment approaches by using EGFR inhibitors with immunotherapy, nanocarriers, and microbiota modulators. Overall, this review highlights the updated role of EGFR signaling as a key regulator of chemoresistance in ovarian cancer, providing insights for developing targeted therapies to overcome drug resistance and improve patient survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmOvarian NeoplasmsSignal TransductionHumansFemaleErbB ReceptorsAnimalsEpithelial-Mesenchymal TransitionAntineoplastic Agents

Stichwörter der Autor:innen

EGFREMTcancer stem cellschemoresistanceovarian cancertargeted therapytumor microenvironment

Substanzen

ErbB ReceptorsEGFR protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pathology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Thandalam, Chennai 602105, Tamil Nadu, India.
  • Department of Orthopaedics, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai 602105, Tamil Nadu, India.
  • PG & Research Department of Biotechnology & Bioinformatics, Holy Cross College (Autonomous), Affiliated to Bharathidasan University, Tiruchirappalli 620002, Tamil Nadu, India.
  • School of Biomedical Convergence Engineering, Pusan National University, Yangsan 50612, Republic of Korea.

ORCID-Profile: Arulkumar Nagappan, Veeran Sethuraman, Parthiban Pandian, Arvind Kumar Shukla

Zitieren

APA

Nagappan, A., Sethuraman, V., Pandian, P., Nedunchezhian, J., & Shukla, A. K. (2026). Oncogenic EGFR Signaling as a Central Regulator of Chemoresistance in Ovarian Cancer: A Mechanistic Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27135937

Vancouver

Nagappan A, Sethuraman V, Pandian P, Nedunchezhian J, Shukla AK. Oncogenic EGFR Signaling as a Central Regulator of Chemoresistance in Ovarian Cancer: A Mechanistic Review. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27135937

BibTeX
@article{Nagappan2026,
  author = {Nagappan, Arulkumar and Sethuraman, Veeran and Pandian, Parthiban and Nedunchezhian, Jothi and Shukla, Arvind Kumar},
  title = {Oncogenic EGFR Signaling as a Central Regulator of Chemoresistance in Ovarian Cancer: A Mechanistic Review},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27135937}
}
Kostenlos starten →